Ryan S. Friese

Ryan S. Friese, Ph.D., has extensive work experience in various scientific and leadership roles. Starting in 2001, they worked as a Graduate Student Researcher at the University of California, San Diego, where they investigated the genetic and molecular mechanisms of essential hypertension. Ryan then became a Postdoctoral Fellow in the Department of Medicine and Institute for Genomic Medicine at the same institution, focusing on research related to hypertension until 2011.

In 2012, Friese joined Pathway Genomics as a Senior Scientist, where they developed DNA-based laboratory tests for oncology and pharmacology. Ryan also played a crucial role in developing the company's clinical cancer variant interpretation and classification algorithm. In addition, they analyzed and assigned clinical risk to genetic variants identified during patient DNA testing for hereditary cancer.

From 2013 to 2015, Friese served as the Founder and CEO of Friese Pharmaceuticals, Inc., a startup pharmaceutical company focused on lead optimization and pre-clinical development of small molecule therapeutics for hypertension. Ryan'sresponsibilities included raising capital, negotiating IP licenses, managing the patent application process, and writing the business plan.

In 2015, Friese joined NanoString Technologies, Inc. as a Pharma Field Application Scientist, eventually becoming a Senior Manager responsible for the West region. Ryan played an integral role in driving sales by delivering pre-sales pitches, seminars, and compelling presentations of pilot project results to customers.

Most recently, Friese joined ROSALIND in 2022. Ryan started as a Strategic Partner Manager before being promoted to Director of Customer Success.

Ryan S. Friese, Ph.D. holds a Ph.D. in Bioengineering from UC San Diego. Ryan also earned a B.S. degree in Biomedical/Biochemical Engineering from the University of Southern California. The exact start and end years of their education are unspecified.